Researchers from Abbvie Inc. recently presented preclinical data for ABBV-706, an SEZ6-targeted topoisomerase 1 (TOP1) inhibitor antibody-drug conjugate (ADC), being developed for the treatment of small-cell lung cancer (SCLC) and other SEZ6-expressing cancers.
Proviva Therapeutics Ltd. scientists hypothesized that both the activation of IL-2 receptor (IL-2R) and the blockade of programmed cell death protein 1 (PD-1) are complementary and potentially synergistic as a combination therapy for treating cancer.
HSN-003839 is a ubiquitin carboxyl-terminal hydrolase 21 (USP21) inhibitor discovered by Beijing Pharscin Innobio Co. Ltd. and being developed as a novel anticancer agent.
Results of preclinical studies with a highly potent KRAS (G12D mutant) inhibitor for the treatment of cancer were recently reported by researchers from Betta Pharmaceuticals Co. Ltd. BPI-501836 displayed higher inhibitory activity at KRAS G12D, when compared to the reference compound (IC50=0.25 and 2.4 nM, respectively) in NanoBRET assays.
Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with poor prognosis and limited therapeutic options, and it accounts for 15%-20% of female invasive breast cancers.
RSS
